Status:
COMPLETED
Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Neurofibromatosis 1
Peripheral Nerve Neoplasms, Malignant
Eligibility:
All Genders
1+ years
Brief Summary
Background: NF1 is a genetic syndrome. Tumors appear early in life. Many people with NF1 develop PN. These tumors can become an aggressive cancer called MPNST. People with MPNST may benefit from trea...
Detailed Description
Study Description: This is a retrospective review that includes all patients with NF1 enrolled on natural history and treatment trials at the National Cancer Institute (NCI) from 1/1/1998 to 1/1/2020,...
Eligibility Criteria
Inclusion
- All participants seen at the NIH from 1/1/1998 to 1/1/2020 with a clinical or laboratory diagnosis of NF1
- Participants beyond the neonatal period (4 weeks).
Exclusion
- All participants seen at the NIH from 1/1/1998 to 1/1/2020 with a clinical or laboratory diagnosis of NF1 who opted out of future use.
Key Trial Info
Start Date :
February 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 8 2022
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT04774289
Start Date
February 24 2021
End Date
December 8 2022
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892